| scholarly article | Q13442814 |
| P50 | author | Dario Giugliano | Q59197360 |
| P2093 | author name string | Raffaele Marfella | |
| Katherine Esposito | |||
| Campanian Postprandial Hyperglycemia Study Group | |||
| Francesco Nappo | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| atherosclerosis | Q12252367 | ||
| hyperglycemia | Q271993 | ||
| P304 | page(s) | 214-219 | |
| P577 | publication date | 2004-06-14 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus | |
| P478 | volume | 110 |
| Q34726941 | 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions |
| Q33913060 | A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. |
| Q34511538 | A randomized crossover study to assess the effect of an oat-rich diet on glycaemic control, plasma lipids and postprandial glycaemia, inflammation and oxidative stress in Type 2 diabetes |
| Q35072984 | A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA" |
| Q38802810 | A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. |
| Q34018145 | A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjects |
| Q36122686 | Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia. |
| Q34579585 | Advanced glycation end products and vascular structure and function |
| Q49824036 | Analysis of Postprandial Glycemia in Relation to Metabolic Compensation and Other Observed Parameters of Outpatients with Type 2 Diabetes Mellitus in the Czech Republic. |
| Q42349595 | Approaches to treatment of type 2 diabetes |
| Q37404577 | Arguments for and against the role of glucose variability in the development of diabetes complications |
| Q42745518 | Assessment of glycemic control: new insights into the evaluation of the diabetic patient |
| Q36392849 | Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality |
| Q39580729 | Association of serum amyloid A with subclinical atherosclerosis in women with gestational diabetes |
| Q38073629 | Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes |
| Q100525165 | Beyond Glycated Hemoglobin: Harnessing Data From Sensor-Based Technology to Improve Glucose Variability, Time in Range and Hypoglycemia in Adult Patients With Type 1 Diabetes |
| Q46758021 | Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study |
| Q46891955 | Blood glucose and cerebrovascular disease in nondiabetic patients |
| Q34030881 | Breaking up prolonged sitting reduces postprandial glucose and insulin responses |
| Q36502062 | Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus |
| Q35137148 | Cardiovascular disease in diabetes: where does glucose fit in? |
| Q55430972 | Cardiovascular disease risk marker responses to breaking up prolonged sedentary time in individuals with paraplegia: the Spinal Cord Injury Move More (SCIMM) randomised crossover laboratory trial protocol. |
| Q38857056 | Cardiovascular effects of anti-diabetes drugs |
| Q28193149 | Cardiovascular protection and prevention in patients with cardiac conditions and diabetes |
| Q38184608 | Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus |
| Q41740997 | Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study |
| Q43409321 | Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. |
| Q36970340 | Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis |
| Q34721194 | Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes |
| Q33628605 | Carotid ultrasonography: A potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients |
| Q46625047 | Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. |
| Q26801671 | Clinical Implications of Glucose Variability: Chronic Complications of Diabetes |
| Q92447415 | Clinical utility of carotid ultrasonography: Application for the management of patients with diabetes |
| Q51493788 | Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk. |
| Q37416127 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. |
| Q36682246 | Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study |
| Q41607262 | Comparison of Glucose Area Under the Curve Measured Using Minimally Invasive Interstitial Fluid Extraction Technology with Continuous Glucose Monitoring System in Diabetic Patients. |
| Q37105144 | Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes |
| Q42654060 | Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus |
| Q56334725 | Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus |
| Q40383846 | Continuous glucose monitoring has left the station: are you onboard? |
| Q37890790 | Control of postprandial glucose levels with insulin in type 2 diabetes |
| Q35644319 | Correlative association of interleukin-6 with intima media thickness: a meta-analysis. |
| Q42707626 | Counterpoint: Postprandial Glucose Levels Are Not a Clinically Important Treatment Target |
| Q36321268 | Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial |
| Q36514257 | Current role of medical treatment and invasive management in carotid atherosclerotic disease |
| Q37111783 | Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. |
| Q82860997 | Determinants of erectile dysfunction in type 2 diabetes |
| Q51572713 | Determinants of female sexual dysfunction in type 2 diabetes. |
| Q37554194 | Diabetes mellitus and gastric emptying: questions and issues in clinical practice |
| Q30416241 | Diabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes |
| Q35828239 | Diabetes-specific nutrition algorithm: a transcultural program to optimize diabetes and prediabetes care |
| Q34829290 | Diabetes: glycaemic control in type 2 (drug treatments). |
| Q33446693 | Diabetes: glycaemic control in type 2. |
| Q35774087 | Diagnostic and prognostic utility of non-invasive imaging in diabetes management |
| Q30354434 | Differences between healthy adults and patients with type 2 diabetes mellitus in reactivity of toe microcirculation by ultrasound combined with a warm bath test |
| Q30666747 | Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes |
| Q46740980 | Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. |
| Q26767164 | Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials |
| Q33773432 | Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes |
| Q37605460 | Effective use of paired testing in type 2 diabetes: practical applications in clinical practice |
| Q57787820 | Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes |
| Q46593004 | Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients |
| Q36633079 | Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial |
| Q37167569 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study |
| Q51496122 | Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. |
| Q46368028 | Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test |
| Q37105140 | Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial |
| Q40844288 | Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials |
| Q64062502 | Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials |
| Q34407865 | Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. |
| Q38258938 | Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus |
| Q39614178 | Evaluation of the future atherosclerotic heart disease with oxidative stress and carotid artery intima media thickness in gestational diabetes mellitus |
| Q37117839 | Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease |
| Q37724502 | Finite element analysis of helical flows in human aortic arch: a novel index |
| Q35085599 | Glucose and triglyceride excursions following a standardized meal in individuals with diabetes: ELSA-Brasil study. |
| Q40124207 | Glucose variability |
| Q36194911 | Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum |
| Q34486820 | Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? |
| Q36578890 | Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients |
| Q39364360 | Glycemic variability: Clinical implications |
| Q34372793 | HbA₁(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. |
| Q36765516 | Hemodynamic changes in postprandial state. |
| Q45886182 | Hepatic insulin gene therapy prevents deterioration of vascular function and improves adipocytokine profile in STZ-diabetic rats |
| Q42053870 | High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity |
| Q36765510 | How should postprandial glycemia be treated? |
| Q47443616 | Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes |
| Q43215429 | Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction |
| Q37427254 | Implementing treatment guidelines for type 2 diabetes in primary care |
| Q42745517 | Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors |
| Q36013146 | Inhaled human insulin (Exubera): clinical profile and patient considerations. |
| Q36269658 | Insulin secretagogues: who, what, when, and how? |
| Q37479419 | Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept |
| Q33753663 | Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data |
| Q45073594 | International Consensus on Use of Continuous Glucose Monitoring. |
| Q37240511 | International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations |
| Q33969587 | Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients? |
| Q30442016 | Is glycemic variability important to assessing antidiabetes therapies? |
| Q37624295 | Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. |
| Q33610682 | Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes |
| Q33687575 | Late cardiovascular consequences of gestational diabetes mellitus |
| Q38511039 | Lipid effects and cardiovascular disease risk associated with glucose-lowering medications. |
| Q46467777 | Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial |
| Q35228483 | Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. |
| Q42678700 | Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide |
| Q36766940 | Mediterranean diet, endothelial function and vascular inflammatory markers |
| Q28242989 | Meglitinide analogues: a review of clinical data focused on recent trials |
| Q36039087 | Metabolic syndrome and other factors associated with increased risk of diabetes |
| Q30252932 | Metrics for glycaemic control - from HbA1c to continuous glucose monitoring |
| Q50871216 | Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. |
| Q27692053 | Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies |
| Q44802551 | Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study |
| Q36902735 | Noninvasive assessment of target organ injury in children with the metabolic syndrome |
| Q43623717 | Novel anti-inflammatory effects of repaglinide in rodent models of inflammation |
| Q53063504 | Oat-enriched diet reduces inflammatory status assessed by circulating cell-derived microparticle concentrations in type 2 diabetes. |
| Q37717838 | On the potential of acarbose to reduce cardiovascular disease |
| Q33514840 | Optimizing display, analysis, interpretation and utility of self-monitoring of blood glucose (SMBG) data for management of patients with diabetes |
| Q37446672 | Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies |
| Q36065338 | Pathophysiology and Medical Treatment of Carotid Artery Stenosis |
| Q37119965 | Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin |
| Q48125653 | Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose-response randomized controlled crossover trial |
| Q37960779 | Post-prandial glucose and diabetic complications: systematic review of observational studies |
| Q38460480 | Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies |
| Q36051229 | Postprandial glucose monitoring further improved glycemia, lipids, and weight in persons with type 2 diabetes mellitus who had already reached hemoglobin A1c goal |
| Q36823771 | Postprandial glycemia and cardiovascular disease in diabetes mellitus |
| Q36632034 | Postprandial hyperglycaemia and vascular damage--the benefits of acarbose |
| Q36493199 | Postprandial hyperglycaemia: to treat or not to treat? |
| Q37464262 | Postprandial hyperglycemia as an etiological factor in vascular failure |
| Q39704946 | Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. |
| Q33896433 | Pramlintide and the treatment of diabetes: a review of the data since its introduction |
| Q58829102 | Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes |
| Q30434101 | Pramlintide reduces the risks associated with glucose variability in type 1 diabetes |
| Q36066526 | Prandial glucose regulation in the glucose triad: emerging evidence and insights |
| Q36269662 | Prandial hyperglycemia: is it important to track and treat? |
| Q43048700 | Pre-mixed rapid-acting insulin 50/50 analogue twice daily is useful not only for controlling post-prandial blood glucose, but also for stabilizing the diurnal variation of blood glucose levels: switching from pre-mixed insulin 70/30 or 75/25 to pre- |
| Q46883811 | Premixed insulin analogues for the treatment of diabetes mellitus |
| Q44991769 | Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. |
| Q37501952 | Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention |
| Q51370461 | Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. |
| Q30438126 | Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine |
| Q89378822 | Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea |
| Q51345186 | Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. |
| Q37977979 | Repaglinide: a review of its use in type 2 diabetes mellitus |
| Q37197094 | Role of postprandial hyperglycemia in cardiovascular disease |
| Q48431494 | Should diabetic patients be asked to test their blood glucose 90 to 120 minutes after the beginning of their meals? |
| Q36417137 | Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? |
| Q34609522 | Strain-blood pressure index for evaluation of early changes in elasticity of anterior tibial artery in patients with type 2 diabetes mellitus |
| Q24186660 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q24197884 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q30244149 | Summation of blood glucose and TAG to characterise the 'metabolic load index'. |
| Q51474535 | Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. |
| Q46381353 | Targeting prandial hyperglycemia: how important is it and how best to do this? |
| Q33390186 | The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein |
| Q38934653 | The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation |
| Q34021697 | The Tsim Tsoum Approaches for Prevention of Cardiovascular Disease |
| Q37978209 | The emerging role of HDL in glucose metabolism |
| Q46881097 | The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q30438605 | The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus |
| Q34133889 | Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors |
| Q37404353 | Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion |
| Q57181583 | Twenty Minute Moderate-Intensity Post-Dinner Exercise Reduces the Postprandial Glucose Response in Chinese Patients with Type 2 Diabetes |
| Q41041665 | Urine Albumin Excretion as a Marker of Acute Glycemic Changes in Isolated Postprandial Hyperglycemia |
| Q37404411 | Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes |
| Q28219328 | Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus |
| Q36985135 | Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes |
| Q58126220 | [Effect of moderate exercise for 30 min at 30 min versus 60 min after dinner on glycemic control in patients with type 2 diabetes: a randomized, crossover, self-controlled study] |
Search more.